阿伐曲泊帕治疗成人早期与慢性免疫性血小板减少症的对比研究
本研究为多中心观察性队列研究,纳入75例接受阿伐曲泊帕治疗的成人免疫性血小板减少症(ITP)患者,比较新诊断/持续性ITP(23例)与慢性ITP(52例)的疗效与安全性。结果显示两组血小板应答率、完全应答率、中位血小板计数及应答持久性均相似,新诊断/持续性组无重大出血、血栓栓塞或药物不良反应停药事件。
要点
- 新诊断/持续性ITP与慢性ITP患者接受阿伐曲泊帕后血小板应答率分别为91%与96%(p=.58),完全应答率分别为86%与81%(p=.78)。
- 两组中位血小板计数相似(165×10⁹/L vs 129×10⁹/L,p=.57),应答持久性均高且相似。
- 新诊断/持续性组无重大出血、血栓栓塞或药物不良反应停药事件,慢性组分别为4例、1例、2例。
核心结论
- 阿伐曲泊帕在新诊断和持续性ITP患者中安全有效,其结局在数值上、统计学上和临床上与因慢性ITP接受阿伐曲泊帕治疗的患者相似。
研究设计与样本
- 多中心观察性队列研究,纳入75例接受阿伐曲泊帕治疗的成人ITP患者,其中新诊断/持续性ITP 23例(阿伐曲泊帕治疗17.7患者年),慢性ITP 52例(阿伐曲泊帕治疗65.3患者年)。
主要发现
- 接受阿伐曲泊帕治疗时,新诊断/持续性组91%的患者 versus 慢性组96%的患者(p=.58)达到血小板应答(≥50×10⁹/L)。
- 新诊断/持续性组86% versus 慢性组81%的患者(p=.78)达到完全应答(≥100×10⁹/L)。
- 两组接受阿伐曲泊帕治疗时的中位血小板计数相似(165×10⁹/L vs 129×10⁹/L,p=.57)。
- 两组应答持久性均高且相似。
- 新诊断/持续性组无患者发生重大出血事件、血栓栓塞事件或因不良事件停用阿伐曲泊帕,慢性组分别为4例、1例、2例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avatrombopag is a newer thrombopoietin receptor agonist (TPO-RA) currently approved to treat chronic ITP (duration >12 months). No studies have yet evaluated the safety and effectiveness of avatrombopag in newly diagnosed ITP (duration <3 months) or persistent ITP (duration 3-12 months), and so its use in these populations is presently off-label worldwide. We hypothesize that avatrombopag has similar safety and effectiveness irrespective of ITP disease phase. To evaluate this, we performed a multicenter observational cohort study of adults with ITP treated with avatrombopag, comparing patient outcomes by disease phase (newly diagnosed/persistent versus chronic). Seventy-five patients were included, 23 with newly diagnosed/persistent ITP (17.7 patient-years of avatrombopag treatment) and 52 with chronic ITP (65.3 patient-years of avatrombopag treatment). On avatrombopag, 91% of newly diagnosed/persistent patients versus 96% of chronic patients (p = .58) achieved a platelet response (≥50 × 109 /L) and 86% versus 81% of patients (p = .78) achieved a complete response (≥100 × 109 /L). Median platelet counts on avatrombopag were similar between the two groups (165 × 109 /L vs. 129 × 109 /L, p = .57). Response durability was high and similar in both groups. No patients in the newly diagnosed/persistent group had a major bleeding event, thromboembolic event or avatrombopag discontinuation for adverse events, compared with 4, 1, and 2, respectively, in the chronic group. Thrombocytosis (platelets ≥400 × 109 /L) incidence was similar in the two groups. No other drug-related adverse events occurred in either group. Avatrombopag was safe and effective in patients with newly diagnosed and persistent ITP, with outcomes numerically, statistically, and clinically similar to patients receiving avatrombopag for chronic ITP.
引用
- Virk ZM, Leaf RK, Kuter DJ, et al. Avatrombopag for adults with early versus chronic immune thrombocytopenia. Am J Hematol. 2023. PMID: 38063420. doi:10.1002/ajh.27080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。